Patrick A. Ott

Featured in: Favicon

nature.com Favicon

thelancet.com Favicon

healio.com Favicon

aacrjournals.org Favicon

ascopubs.org Favicon

amegroups.com Favicon

onclive.com Favicon

cancerdiscovery.aacrjournals.org Favicon

cco.amegroups.com

Articles

Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors

Mar 1, 2024 | jitc.bmj.com | Nikhil I. Khushalani |Patrick A. Ott |Robert Ferris |Tina Cascone

DiscussionWe report here data from two phase 1/2 trials that aimed to evaluate the safety, tolerability, PK, PD, immunogenicity, and preliminary efficacy of novel combinations of urelumab with cetuximab (CA186-018) or nivolumab (CA186-107). The combination of urelumab-0.1 or urelumab-8 with cetuximab-240 was well tolerated and did not appear to have additive toxicity profiles beyond the expected safety profile of cetuximab.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →